Influence of patient characteristics on GPs advice on stopping statins in oldest-old: survey study across GPs from 30 countries

A. Howe; A. Murphy; Ross Murtagh; D. Swan; Eileen O'Connor; G. McCombe; C. Murphy; J. Lambert; Gordana Avramovic; W. Cullen; E. Hummers-Pradier; Michaela Aschenbrenner; Ildikó Gágyor; Jutta Bleidorn; S. Heim; Guido Schmiemann; C. Collins; James Larkin; Ivana Pericin; B. Osborne; P. Dodd; A. Jennings; T. Foley; S. McHugh; J. Browne; C. Bradley; Miroslav Hanževački; Sven Streit; Rosalinde Poortvliet; Jacobijn Gussekloo; P. Nabbe; J. oDoherty; Jennifer Gettings; Robyn M. oConnor; A. Hannigan; L. Hickey; A. ORegan; Yochai Schonmann; Or Goren; Ronen Bareket; Doron Comaneshter; A. Cohen; Shlomo Vinker; L. Pas; Trudy Bekkering; Evelien Lenaerts; C. Mathei; B. Aertgeerts; J. S. Cadwallader; Massimiliano Orri; C. Hassler; C. Barry; B. Falissard; Caroline Huas; Anja Cerne; Davorina Petek; P. Selič; Ailis Ni Riain; T. O'Sullivan; Gerard Mansfield; O. Gonzalez; Aine Waters; James Keogh; Nora Kavanagh; Clare ONeill; G. McGuire; M. Kelly; Anna Berenguera; Enriqueta Pujol-Ribera; Victòria Carmona-Terés; Mariona Pons-Vigués; Joana Moix-Queraltó; Anna Neary; E. Beary; E. McCarron; Leanne Hanrahan; O. Murphy; P. Ruane; Bibiana Savin; B. O'Shea; A. Ní Shúilleabháin; Aelita Skarbalieo; Teresa Pawlikovska; Eva Lena Strandberg; A. Jurgutis; Cedric Rat; Aurelie Gaultier; J. Nguyen; C. Berkhout; Amy Willefert-Bouche; E. Chazard; Suzanna Zgorska-Maynard Moussa; Favre Jonathan; L. Peremans; Gregoire Ficheur; P. Van Royen; Milly Anna Altena-Van Der Ploeg; Nettie Blankenstein; E. Beers; Arthur Bohnen; D. Bonfim; Huib Burger; R. Burman; Tuz Canan; F. G. de Mello Franco; M. D. de Waal; Biljana Gerasimovska-Kitanovska; Sandra Gintere; R. Bravo; K. Hoffmann; Claudia Iftode; Kasper Johansen; T. Koskela; D. Kurpas; H. Maisonneuve; C. Mallen; Christoph Merlo; Y. Mueller; C. Muth; Martin Sattler; Sanda K Peštić; Ferdinando Petrazzuoli; N. Rodondi; T. Rosemann; T. Schermer; Marija Petek Šter; Z. Švadlenková; Athina Tatsioni; H. Thulesius; Victoria Tkachenko; P. Torzsa; Rosy Tsopra; B. Vaes; M. van den Akker; R. Viegas; K. Wallis; A. Zeller; Heloise Schmeltz; S. Rocher; M. Beyer; L. Uhlmann; C. Guethlin; M. Hammer; F. Gerlach; Karimova Kateryna

Influence of patient characteristics on GPs advice on stopping statins in oldest-old: survey study across GPs from 30 countries

A. Howe, A. Murphy, Ross Murtagh, D. Swan, Eileen O'Connor, G. McCombe, C. Murphy, J. Lambert, Gordana Avramovic, W. Cullen, E. Hummers-Pradier, Michaela Aschenbrenner, Ildikó Gágyor, Jutta Bleidorn, S. Heim, Guido Schmiemann, C. Collins, James Larkin, Ivana Pericin, B. OsborneP. Dodd, A. Jennings, T. Foley, S. McHugh, J. Browne, C. Bradley, Miroslav Hanževački, Sven Streit, Rosalinde Poortvliet, Jacobijn Gussekloo, P. Nabbe, J. oDoherty, Jennifer Gettings, Robyn M. oConnor, A. Hannigan, L. Hickey, A. ORegan, Yochai Schonmann, Or Goren, Ronen Bareket, Doron Comaneshter, A. Cohen, Shlomo Vinker, L. Pas, Trudy Bekkering, Evelien Lenaerts, C. Mathei, B. Aertgeerts, J. S. Cadwallader, Massimiliano Orri, C. Hassler, C. Barry, B. Falissard, Caroline Huas, Anja Cerne, Davorina Petek, P. Selič, Ailis Ni Riain, T. O'Sullivan, Gerard Mansfield, O. Gonzalez, Aine Waters, James Keogh, Nora Kavanagh, Clare ONeill, G. McGuire, M. Kelly, Anna Berenguera, Enriqueta Pujol-Ribera, Victòria Carmona-Terés, Mariona Pons-Vigués, Joana Moix-Queraltó, Anna Neary, E. Beary, E. McCarron, Leanne Hanrahan, O. Murphy, P. Ruane, Bibiana Savin, B. O'Shea, A. Ní Shúilleabháin, Aelita Skarbalieo, Teresa Pawlikovska, Eva Lena Strandberg, A. Jurgutis, Cedric Rat, Aurelie Gaultier, J. Nguyen, C. Berkhout, Amy Willefert-Bouche, E. Chazard, Suzanna Zgorska-Maynard Moussa, Favre Jonathan, L. Peremans, Gregoire Ficheur, P. Van Royen, Milly Anna Altena-Van Der Ploeg, Nettie Blankenstein, E. Beers, Arthur Bohnen, D. Bonfim, Huib Burger, R. Burman, Tuz Canan, F. G. de Mello Franco, M. D. de Waal, Biljana Gerasimovska-Kitanovska, Sandra Gintere, R. Bravo, K. Hoffmann, Claudia Iftode, Kasper Johansen, T. Koskela, D. Kurpas, H. Maisonneuve, C. Mallen, Christoph Merlo, Y. Mueller, C. Muth, Martin Sattler, Sanda K Peštić, Ferdinando Petrazzuoli, N. Rodondi, T. Rosemann, T. Schermer, Marija Petek Šter, Z. Švadlenková, Athina Tatsioni, H. Thulesius, Victoria Tkachenko, P. Torzsa, Rosy Tsopra, B. Vaes, M. van den Akker, R. Viegas, K. Wallis, A. Zeller, Heloise Schmeltz, S. Rocher, M. Beyer, L. Uhlmann, C. Guethlin, M. Hammer, F. Gerlach, Karimova Kateryna

NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)

Research output: Contribution to journal › Meeting Abstract › peer-review

Abstract

Background: Statins are widely used to prevent cardiovascular disease (CVD). Current guidelines give little advice on when to stop statin treatment. GPs must rely on other factors like patient characteristics or common practice when making treatment decisions. Research questions: Do patient-related characteristics (frailty, statin-related side effects, history of CVD or limited life expectancy) influence GPs’ advice to stop statins in the oldest old (>80 years)? Does advice vary across countries? Methods: GPs from 30 countries (27 in Europe, Brazil, Israel, and New Zealand) participated in a survey based on case vignettes. We compared treatment advice in cases of >80 years varying in frailty, statin-related side effects, history of CVD and life expectancy <1 year. We compared the percentage of cases per GP that would be advised to stop. We used mixed-effect models to calculate odd ratio’s (ORsadj) adjusted for GP characteristics (such as gender) as fixed effects; country and GPs were adjusted as random effects. Results: n = 2250. When no information about life expectancy was given, GPs advised stopping statin treatment in 46% of the cases (range: 23–58% across countries). When ‘life expectancy <1 year’ was added to case descriptions, GPs advised stopping statins in an additional 82% of the cases (range: 30–98% across countries). Frailty, side effects and life expectancy were associated with increased advice to stop (ORadj: 4.1; 95%CI: 3.8–4.4; ORadj: 1.62; 95%CI: 1.5–1.7 ORadj: 50.7; 95%CI: 45.5–56.4, respectively), while history of CVD was strongly related with decreased advice to stop (ORadj: 0.07; 95%CI: 0.07–0.08). Conclusion: GPs were more likely to advise stopping statin treatment in >80 year-old patients when patients were frail, suffering statin side effects or had limited life expectancy; and more likely to continue statin treatment as secondary prevention for CVD. There were considerable treatment variations across countries.

Original language	English
Pages (from-to)	211 - 222
Journal	European Journal of General Practice
Volume	24
Issue number	1
Publication status	Published - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Howe, A., Murphy, A., Murtagh, R., Swan, D., O'Connor, E., McCombe, G., Murphy, C., Lambert, J., Avramovic, G., Cullen, W., Hummers-Pradier, E., Aschenbrenner, M., Gágyor, I., Bleidorn, J., Heim, S., Schmiemann, G., Collins, C., Larkin, J., Pericin, I., ... Kateryna, K. (2018). Influence of patient characteristics on GPs advice on stopping statins in oldest-old: survey study across GPs from 30 countries. European Journal of General Practice, 24(1), 211 - 222.

@article{6c04a63845064af1b3995d90e9b89e40,

title = "Influence of patient characteristics on GPs advice on stopping statins in oldest-old: survey study across GPs from 30 countries",

abstract = " Background: Statins are widely used to prevent cardiovascular disease (CVD). Current guidelines give little advice on when to stop statin treatment. GPs must rely on other factors like patient characteristics or common practice when making treatment decisions. Research questions: Do patient-related characteristics (frailty, statin-related side effects, history of CVD or limited life expectancy) influence GPs{\textquoteright} advice to stop statins in the oldest old (>80 years)? Does advice vary across countries? Methods: GPs from 30 countries (27 in Europe, Brazil, Israel, and New Zealand) participated in a survey based on case vignettes. We compared treatment advice in cases of >80 years varying in frailty, statin-related side effects, history of CVD and life expectancy <1 year. We compared the percentage of cases per GP that would be advised to stop. We used mixed-effect models to calculate odd ratio{\textquoteright}s (ORsadj) adjusted for GP characteristics (such as gender) as fixed effects; country and GPs were adjusted as random effects. Results: n = 2250. When no information about life expectancy was given, GPs advised stopping statin treatment in 46% of the cases (range: 23–58% across countries). When {\textquoteleft}life expectancy <1 year{\textquoteright} was added to case descriptions, GPs advised stopping statins in an additional 82% of the cases (range: 30–98% across countries). Frailty, side effects and life expectancy were associated with increased advice to stop (ORadj: 4.1; 95%CI: 3.8–4.4; ORadj: 1.62; 95%CI: 1.5–1.7 ORadj: 50.7; 95%CI: 45.5–56.4, respectively), while history of CVD was strongly related with decreased advice to stop (ORadj: 0.07; 95%CI: 0.07–0.08). Conclusion: GPs were more likely to advise stopping statin treatment in >80 year-old patients when patients were frail, suffering statin side effects or had limited life expectancy; and more likely to continue statin treatment as secondary prevention for CVD. There were considerable treatment variations across countries.",

author = "A. Howe and A. Murphy and Ross Murtagh and D. Swan and Eileen O'Connor and G. McCombe and C. Murphy and J. Lambert and Gordana Avramovic and W. Cullen and E. Hummers-Pradier and Michaela Aschenbrenner and Ildik{\'o} G{\'a}gyor and Jutta Bleidorn and S. Heim and Guido Schmiemann and C. Collins and James Larkin and Ivana Pericin and B. Osborne and P. Dodd and A. Jennings and T. Foley and S. McHugh and J. Browne and C. Bradley and Miroslav Han{\v z}eva{\v c}ki and Sven Streit and Rosalinde Poortvliet and Jacobijn Gussekloo and P. Nabbe and J. oDoherty and Jennifer Gettings and oConnor, {Robyn M.} and A. Hannigan and L. Hickey and A. ORegan and Yochai Schonmann and Or Goren and Ronen Bareket and Doron Comaneshter and A. Cohen and Shlomo Vinker and L. Pas and Trudy Bekkering and Evelien Lenaerts and C. Mathei and B. Aertgeerts and Cadwallader, {J. S.} and Massimiliano Orri and C. Hassler and C. Barry and B. Falissard and Caroline Huas and Anja Cerne and Davorina Petek and P. Seli{\v c} and Riain, {Ailis Ni} and T. O'Sullivan and Gerard Mansfield and O. Gonzalez and Aine Waters and James Keogh and Nora Kavanagh and Clare ONeill and G. McGuire and M. Kelly and Anna Berenguera and Enriqueta Pujol-Ribera and Vict{\`o}ria Carmona-Ter{\'e}s and Mariona Pons-Vigu{\'e}s and Joana Moix-Queralt{\'o} and Anna Neary and E. Beary and E. McCarron and Leanne Hanrahan and O. Murphy and P. Ruane and Bibiana Savin and B. O'Shea and Sh{\'u}illeabh{\'a}in, {A. N{\'i}} and Aelita Skarbalieo and Teresa Pawlikovska and Strandberg, {Eva Lena} and A. Jurgutis and Cedric Rat and Aurelie Gaultier and J. Nguyen and C. Berkhout and Amy Willefert-Bouche and E. Chazard and Moussa, {Suzanna Zgorska-Maynard} and Favre Jonathan and L. Peremans and Gregoire Ficheur and Royen, {P. Van} and Ploeg, {Milly Anna Altena-Van Der} and Nettie Blankenstein and E. Beers and Arthur Bohnen and D. Bonfim and Huib Burger and R. Burman and Tuz Canan and Franco, {F. G. de Mello} and Waal, {M. D. de} and Biljana Gerasimovska-Kitanovska and Sandra Gintere and R. Bravo and K. Hoffmann and Claudia Iftode and Kasper Johansen and T. Koskela and D. Kurpas and H. Maisonneuve and C. Mallen and Christoph Merlo and Y. Mueller and C. Muth and Martin Sattler and Pe{\v s}ti{\'c}, {Sanda K} and Ferdinando Petrazzuoli and N. Rodondi and T. Rosemann and T. Schermer and {\v S}ter, {Marija Petek} and Z. {\v S}vadlenkov{\'a} and Athina Tatsioni and H. Thulesius and Victoria Tkachenko and P. Torzsa and Rosy Tsopra and B. Vaes and Akker, {M. van den} and R. Viegas and K. Wallis and A. Zeller and Heloise Schmeltz and S. Rocher and M. Beyer and L. Uhlmann and C. Guethlin and M. Hammer and F. Gerlach and Karimova Kateryna",

year = "2018",

language = "English",

volume = "24",

pages = "211 -- 222",

journal = " European Journal of General Practice",

publisher = "Taylor & Francis Group",

number = "1",

}

Howe, A, Murphy, A, Murtagh, R, Swan, D, O'Connor, E, McCombe, G, Murphy, C, Lambert, J, Avramovic, G, Cullen, W, Hummers-Pradier, E, Aschenbrenner, M, Gágyor, I, Bleidorn, J, Heim, S, Schmiemann, G, Collins, C, Larkin, J, Pericin, I, Osborne, B, Dodd, P, Jennings, A, Foley, T, McHugh, S, Browne, J, Bradley, C, Hanževački, M, Streit, S, Poortvliet, R, Gussekloo, J, Nabbe, P, oDoherty, J, Gettings, J, oConnor, RM, Hannigan, A, Hickey, L, ORegan, A, Schonmann, Y, Goren, O, Bareket, R, Comaneshter, D, Cohen, A, Vinker, S, Pas, L, Bekkering, T, Lenaerts, E, Mathei, C, Aertgeerts, B, Cadwallader, JS, Orri, M, Hassler, C, Barry, C, Falissard, B, Huas, C, Cerne, A, Petek, D, Selič, P, Riain, AN, O'Sullivan, T, Mansfield, G, Gonzalez, O, Waters, A, Keogh, J, Kavanagh, N, ONeill, C, McGuire, G, Kelly, M, Berenguera, A, Pujol-Ribera, E, Carmona-Terés, V, Pons-Vigués, M, Moix-Queraltó, J, Neary, A, Beary, E, McCarron, E, Hanrahan, L, Murphy, O, Ruane, P, Savin, B, O'Shea, B, Shúilleabháin, AN, Skarbalieo, A, Pawlikovska, T, Strandberg, EL, Jurgutis, A, Rat, C, Gaultier, A, Nguyen, J, Berkhout, C, Willefert-Bouche, A, Chazard, E, Moussa, SZ-M, Jonathan, F, Peremans, L, Ficheur, G, Royen, PV, Ploeg, MAA-VD, Blankenstein, N, Beers, E, Bohnen, A, Bonfim, D, Burger, H, Burman, R, Canan, T, Franco, FGDM, Waal, MDD, Gerasimovska-Kitanovska, B, Gintere, S, Bravo, R, Hoffmann, K, Iftode, C, Johansen, K, Koskela, T, Kurpas, D, Maisonneuve, H, Mallen, C, Merlo, C, Mueller, Y, Muth, C, Sattler, M, Peštić, SK, Petrazzuoli, F, Rodondi, N, Rosemann, T, Schermer, T, Šter, MP, Švadlenková, Z, Tatsioni, A, Thulesius, H, Tkachenko, V, Torzsa, P, Tsopra, R, Vaes, B, Akker, MVD, Viegas, R, Wallis, K, Zeller, A, Schmeltz, H, Rocher, S, Beyer, M, Uhlmann, L, Guethlin, C, Hammer, M, Gerlach, F & Kateryna, K 2018, 'Influence of patient characteristics on GPs advice on stopping statins in oldest-old: survey study across GPs from 30 countries', European Journal of General Practice, vol. 24, no. 1, pp. 211 - 222.

TY - JOUR

T1 - Influence of patient characteristics on GPs advice on stopping statins in oldest-old

T2 - survey study across GPs from 30 countries

AU - Howe, A.

AU - Murphy, A.

AU - Murtagh, Ross

AU - Swan, D.

AU - O'Connor, Eileen

AU - McCombe, G.

AU - Murphy, C.

AU - Lambert, J.

AU - Avramovic, Gordana

AU - Cullen, W.

AU - Hummers-Pradier, E.

AU - Aschenbrenner, Michaela

AU - Gágyor, Ildikó

AU - Bleidorn, Jutta

AU - Heim, S.

AU - Schmiemann, Guido

AU - Collins, C.

AU - Larkin, James

AU - Pericin, Ivana

AU - Osborne, B.

AU - Dodd, P.

AU - Jennings, A.

AU - Foley, T.

AU - McHugh, S.

AU - Browne, J.

AU - Bradley, C.

AU - Hanževački, Miroslav

AU - Streit, Sven

AU - Poortvliet, Rosalinde

AU - Gussekloo, Jacobijn

AU - Nabbe, P.

AU - oDoherty, J.

AU - Gettings, Jennifer

AU - oConnor, Robyn M.

AU - Hannigan, A.

AU - Hickey, L.

AU - ORegan, A.

AU - Schonmann, Yochai

AU - Goren, Or

AU - Bareket, Ronen

AU - Comaneshter, Doron

AU - Cohen, A.

AU - Vinker, Shlomo

AU - Pas, L.

AU - Bekkering, Trudy

AU - Lenaerts, Evelien

AU - Mathei, C.

AU - Aertgeerts, B.

AU - Cadwallader, J. S.

AU - Orri, Massimiliano

AU - Hassler, C.

AU - Barry, C.

AU - Falissard, B.

AU - Huas, Caroline

AU - Cerne, Anja

AU - Petek, Davorina

AU - Selič, P.

AU - Riain, Ailis Ni

AU - O'Sullivan, T.

AU - Mansfield, Gerard

AU - Gonzalez, O.

AU - Waters, Aine

AU - Keogh, James

AU - Kavanagh, Nora

AU - ONeill, Clare

AU - McGuire, G.

AU - Kelly, M.

AU - Berenguera, Anna

AU - Pujol-Ribera, Enriqueta

AU - Carmona-Terés, Victòria

AU - Pons-Vigués, Mariona

AU - Moix-Queraltó, Joana

AU - Neary, Anna

AU - Beary, E.

AU - McCarron, E.

AU - Hanrahan, Leanne

AU - Murphy, O.

AU - Ruane, P.

AU - Savin, Bibiana

AU - O'Shea, B.

AU - Shúilleabháin, A. Ní

AU - Skarbalieo, Aelita

AU - Pawlikovska, Teresa

AU - Strandberg, Eva Lena

AU - Jurgutis, A.

AU - Rat, Cedric

AU - Gaultier, Aurelie

AU - Nguyen, J.

AU - Berkhout, C.

AU - Willefert-Bouche, Amy

AU - Chazard, E.

AU - Moussa, Suzanna Zgorska-Maynard

AU - Jonathan, Favre

AU - Peremans, L.

AU - Ficheur, Gregoire

AU - Royen, P. Van

AU - Ploeg, Milly Anna Altena-Van Der

AU - Blankenstein, Nettie

AU - Beers, E.

AU - Bohnen, Arthur

AU - Bonfim, D.

AU - Burger, Huib

AU - Burman, R.

AU - Canan, Tuz

AU - Franco, F. G. de Mello

AU - Waal, M. D. de

AU - Gerasimovska-Kitanovska, Biljana

AU - Gintere, Sandra

AU - Bravo, R.

AU - Hoffmann, K.

AU - Iftode, Claudia

AU - Johansen, Kasper

AU - Koskela, T.

AU - Kurpas, D.

AU - Maisonneuve, H.

AU - Mallen, C.

AU - Merlo, Christoph

AU - Mueller, Y.

AU - Muth, C.

AU - Sattler, Martin

AU - Peštić, Sanda K

AU - Petrazzuoli, Ferdinando

AU - Rodondi, N.

AU - Rosemann, T.

AU - Schermer, T.

AU - Šter, Marija Petek

AU - Švadlenková, Z.

AU - Tatsioni, Athina

AU - Thulesius, H.

AU - Tkachenko, Victoria

AU - Torzsa, P.

AU - Tsopra, Rosy

AU - Vaes, B.

AU - Akker, M. van den

AU - Viegas, R.

AU - Wallis, K.

AU - Zeller, A.

AU - Schmeltz, Heloise

AU - Rocher, S.

AU - Beyer, M.

AU - Uhlmann, L.

AU - Guethlin, C.

AU - Hammer, M.

AU - Gerlach, F.

AU - Kateryna, Karimova

PY - 2018

Y1 - 2018

N2 - Background: Statins are widely used to prevent cardiovascular disease (CVD). Current guidelines give little advice on when to stop statin treatment. GPs must rely on other factors like patient characteristics or common practice when making treatment decisions. Research questions: Do patient-related characteristics (frailty, statin-related side effects, history of CVD or limited life expectancy) influence GPs’ advice to stop statins in the oldest old (>80 years)? Does advice vary across countries? Methods: GPs from 30 countries (27 in Europe, Brazil, Israel, and New Zealand) participated in a survey based on case vignettes. We compared treatment advice in cases of >80 years varying in frailty, statin-related side effects, history of CVD and life expectancy <1 year. We compared the percentage of cases per GP that would be advised to stop. We used mixed-effect models to calculate odd ratio’s (ORsadj) adjusted for GP characteristics (such as gender) as fixed effects; country and GPs were adjusted as random effects. Results: n = 2250. When no information about life expectancy was given, GPs advised stopping statin treatment in 46% of the cases (range: 23–58% across countries). When ‘life expectancy <1 year’ was added to case descriptions, GPs advised stopping statins in an additional 82% of the cases (range: 30–98% across countries). Frailty, side effects and life expectancy were associated with increased advice to stop (ORadj: 4.1; 95%CI: 3.8–4.4; ORadj: 1.62; 95%CI: 1.5–1.7 ORadj: 50.7; 95%CI: 45.5–56.4, respectively), while history of CVD was strongly related with decreased advice to stop (ORadj: 0.07; 95%CI: 0.07–0.08). Conclusion: GPs were more likely to advise stopping statin treatment in >80 year-old patients when patients were frail, suffering statin side effects or had limited life expectancy; and more likely to continue statin treatment as secondary prevention for CVD. There were considerable treatment variations across countries.

AB - Background: Statins are widely used to prevent cardiovascular disease (CVD). Current guidelines give little advice on when to stop statin treatment. GPs must rely on other factors like patient characteristics or common practice when making treatment decisions. Research questions: Do patient-related characteristics (frailty, statin-related side effects, history of CVD or limited life expectancy) influence GPs’ advice to stop statins in the oldest old (>80 years)? Does advice vary across countries? Methods: GPs from 30 countries (27 in Europe, Brazil, Israel, and New Zealand) participated in a survey based on case vignettes. We compared treatment advice in cases of >80 years varying in frailty, statin-related side effects, history of CVD and life expectancy <1 year. We compared the percentage of cases per GP that would be advised to stop. We used mixed-effect models to calculate odd ratio’s (ORsadj) adjusted for GP characteristics (such as gender) as fixed effects; country and GPs were adjusted as random effects. Results: n = 2250. When no information about life expectancy was given, GPs advised stopping statin treatment in 46% of the cases (range: 23–58% across countries). When ‘life expectancy <1 year’ was added to case descriptions, GPs advised stopping statins in an additional 82% of the cases (range: 30–98% across countries). Frailty, side effects and life expectancy were associated with increased advice to stop (ORadj: 4.1; 95%CI: 3.8–4.4; ORadj: 1.62; 95%CI: 1.5–1.7 ORadj: 50.7; 95%CI: 45.5–56.4, respectively), while history of CVD was strongly related with decreased advice to stop (ORadj: 0.07; 95%CI: 0.07–0.08). Conclusion: GPs were more likely to advise stopping statin treatment in >80 year-old patients when patients were frail, suffering statin side effects or had limited life expectancy; and more likely to continue statin treatment as secondary prevention for CVD. There were considerable treatment variations across countries.

M3 - Meeting Abstract

VL - 24

SP - 211

EP - 222

JO - European Journal of General Practice

JF - European Journal of General Practice

IS - 1

ER -

Influence of patient characteristics on GPs advice on stopping statins in oldest-old: survey study across GPs from 30 countries

Abstract

UN SDGs

Fingerprint

Cite this